Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T

Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T

Chimeric antigen receptor (CAR) T cell therapy represents the first U.S. Food and Drug Administration approved gene therapy and these engineered cells function with unprecedented efficacy in the treatment of refractory CD19 positive hematologic malignancies. CAR translation to solid tumors is also b...

Full description

Bibliographic Details
Main Authors: Dok Hyun Yoon, Mark J. Osborn, Jakub Tolar, Chong Jai Kim
Format: Article
Language:English
Published: MDPI AG 2018-01-01
Series:International Journal of Molecular Sciences
Subjects:
adoptive T cell therapy
chimeric antigen receptors
PD-1
immune-checkpoint
cancer immunotherapy
gene editing
gene therapy
CRISPR/Cas9
Online Access:http://www.mdpi.com/1422-0067/19/2/340

Internet

http://www.mdpi.com/1422-0067/19/2/340

Similar Items